Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ABO Incompatible Deceased Donor Liver Transplants in Infants (Age < 1 Year): A Single-Center Experience.

Pediatric transplantation·2026

Same author

Trends in cryoprecipitate transfusion in the United States.

Transfusion·2026

Same author

The clinical use of cryoprecipitate and fibrinogen concentrate: A scoping review.

Transfusion·2026

Same author

HIV Transmission in a Declining African Epidemic.

medRxiv : the preprint server for health sciences·2026

Same author

Allograft Rejection and the Latent HIV Reservoir in Kidney Transplant Recipients with HIV.

The Journal of infectious diseases·2026

Same author

Patterns of HIV-1 viral load suppression and drug resistance during the dolutegravir transition: a population-based longitudinal study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026

Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026

Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026

Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026

Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026

Same journal

A step toward streamlining HIT diagnosis.

Blood·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 15, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

COVID-19 convalescent plasma.

Aaron A R Tobian¹, Claudia S Cohn², Beth H Shaz³

¹Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD.

|October 25, 2021

Summary

This summary is machine-generated.

COVID-19 convalescent plasma (CCP) shows benefits for early-stage disease in elderly outpatients, especially when high-titer and administered within 72 hours. It is not effective for moderate to severe hospitalized cases.

More Related Videos

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals

Published on: January 5, 2016

Related Experiment Videos

Last Updated: Oct 15, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals

Published on: January 5, 2016

Area of Science:

Immunology
Infectious Diseases
Hematology

Background:

The COVID-19 pandemic presented a global health crisis with limited treatment options.
Convalescent plasma (CP) emerged as a rapidly implementable therapy with a favorable safety profile.
COVID-19 convalescent plasma (CCP) therapeutic potential is attributed to neutralizing antibodies and Fc-dependent functions.

Purpose of the Study:

To evaluate the efficacy of COVID-19 convalescent plasma (CCP) as a treatment for SARS-CoV-2 infection.
To determine optimal indications for CCP transfusion based on disease severity and patient population.
To assess the role of antibody titer and proximity of plasma collection in therapeutic outcomes.

Main Methods:

Review of randomized controlled trials and clinical data on CCP transfusions.
Analysis of therapeutic benefits based on disease stage, patient demographics, and time of administration.
Consideration of antibody titers and potential impact of SARS-CoV-2 variants.

Main Results:

Over half a million units of CCP were transfused in the US despite limited initial efficacy data.
Multiple randomized trials indicate CCP provides no benefit for hospitalized patients with moderate to severe COVID-19.
CCP is beneficial for early disease in elderly outpatients within 72 hours of symptom onset and for immunosuppressed individuals.

Conclusions:

High-titer CCP should be transfused, prioritizing early disease intervention in specific patient groups.
CCP may be more effective when collected closer in time and location to the recipient due to evolving SARS-CoV-2 variants.
Further data from ongoing trials are needed to refine CCP indications and optimize its use in managing COVID-19.